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The hydroxylation of C-1 in nogalamycin is an essential step in its biosynthesis. Siitonen and colleagues,
in this issue of Chemistry & Biology, reveal an unconventional mechanism for the hydroxylation of the
30,40-demethoxy-nogalose-nogalamycinone by a two-component monoxygenase SnoaW/SnoaL2.Aromatic polyketides synthesized by
type II polyketide synthases (PKSs)
comprise an important class of natural
products. According to their polyphenolic
ring structures, type II PKS-derived
aromatic compounds are classified as
anthracyclines, angucyclines, aureolic
acids, tetracyclines, tetracenomycins,
pradimicin-type polyphenols, and benzoi-
sochromanequinones (Hertweck et al.,
2007). The anthracycline family includes
several clinically important drugs, such
as doxorubicin, daunorubicin, and aclaci-
nomycin A, which are among the most
effective anticancer drugs available with
antitumor activity against a variety of solid
tumors, like carcinomas and sarcomas,
and hematological malignancies, such
as leukemias and lymphomas (Weiss,
1992). Anthracyclines consist of a planar
tetracyclic aglycone moiety with adjacent
quinine-hydroquinone groups in rings
C-B, a methoxy substituent at C-4 in ring
D, and a short side chain at C-9 with
a carbonyl at C-13, as well as one or two
sugar moieties, most commonly attached
at the C-7 position via a glycoside bond
(Figure 1).The structural diversity of an-
thracyclines is generated by different
modification patterns of the aromatic pol-
yketide scaffold. The reactions lead to
different substitutions on the aglycone,
including methylation, hydroxylation, re-
duction, and glycosylation. Nagalamycin,
an anthracyline produced by Strepto-
myces nogalater, was reported to pos-
sess high activity against several cancer
cell lines, but its clinical trial was stopped
due to high toxicity (Wiley et al., 1977).
Nogalamycin differs from most other an-
thracyclines in several unique character-
istics, including different stereochemistry
at C-9 (C-9S rather than C-9R), a methylinstead of an ethyl group at C-9, and a
highly unusual nogalamine (3,6-dideoxy-
3-dimethylaminosugar) moiety; C-10 of
nogalamine is attached to the oxygen at
C-1 and C-50 is connected to C-2 by
a C-C bond.
The antitumor activity of anthracyclines
ismainly attributed to their ability to rapidly
diffuse to the nucleus and form the
anthracycline-DNA-topoisomerase ternary
complex by DNA intercalation. The forma-
tion of this complex causes a double-
strand DNA break and interferes with
biosynthesis of DNA, RNA, and protein,
leading ultimately to cell death (Minotti
et al., 2004). Both the planar ring and the
deoxy sugar moiety of anthracyclines are
important for their DNA intercalation.
X-ray and NMR structures of nogalamy-
cin-DNA complexes have shown that the
tetracyclic ring of nogalamycin intercalates
into theDNA,with its nogalose sugar found
in the DNA minor groove while its tetracy-
clic aglycone and bicyclic amino sugar
occupy the DNA major groove (Williams
and Searle, 1999). Menogaril, a semisyn-
thetic derivative of nogalamycin, differs
from the latter compound only in the noga-
lose sugar. However, this difference
changes the cellular activity and toxicity.
Nogalamycin is specifically lethal to the
S-phase cells, while menogaril is toxic to
cells of all phases. Nogalamycin inhibits
RNA synthesis more than DNA synthesis
while menogaril inhibits DNA synthesis
more than RNA synthesis (Li and Krueger,
1991).
Although some anthracyclines are
commonly used in the treatment of many
malignancies, their clinical effectiveness
is greatly limited by the important side
effects, such as dilative cardiomyopathy
and congestive heart failure (Singal andChemistry & Biology 19, May 25, 2012Iliskovic, 1998), and by the development
of multidrug resistance (Kaye and Merry,
1985). Attempts to find anthracyclines
with improved activity or reduced toxicity
has resulted only in a few valuable
compounds. With the advent of molecular
techniques and the fast-increasing knowl-
edge about the pathways and enzymes
for polyketide biosynthesis, post-PKS
modification of the anthracycline agly-
cones might be possible to generate
a series of ‘‘better anthracyclines’’.
A remarkable feature in nogalamycin
biosynthesis is the hydroxylation at the
C-1 position, catalyzed by the two-
component monooxygenase system
SnoaW/SnoaL2 (Siitonen et al., 2012, in
this issue ofChemistry &Biology). Hydrox-
ylation at C-1 of 30,40-demethoxy-noga-
lose-nogalamycinone provides a site for
the following attachment of the nogal-
amine sugar. Modifications at C1/C2 of
anthracyclines are quite attractive,
because these positions have not been
touched in generating novel anthracy-
clines so far (Preobrazhenskaya et al.,
2006). Monooxygenases catalyze the
incorporation of one oxygen atom from
molecular oxygen into the organic
substrate. In order to perform this reac-
tion, monooxygenases have to activate
O2, as no reaction will occur without acti-
vation due to the ‘‘spin- barrier’’ of molec-
ular oxygen (Fetzner and Steiner, 2010). In
order to overcome the barrier, most
monooxygenases depend on transition
metal ions [most often iron (II) or iron (III)
or organic cofactors, such as flavin and
pterin] for catalysis. However, more and
more monooxygenases have been char-
acterized that require neither a cofactor
nor a metal ion, which raises the intriguing
question of how these enzymes work.ª2012 Elsevier Ltd All rights reserved 549
Figure 1. Structures of Selected Anthracyclines and the C-1 Hydroxylation Reaction Catalyzed by SnoaW/SnoaL2
Upon incubation, 3040-demethoxy-nogalose-nogalamycinone undergoes a hydroxylation, resulting in the introduction of an oxygen atom at C-1.
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Siitonen et al. (2012) report a two-com-
ponent monooxygenase SnoaW/SnoaL2
which is responsible for the C-1 hydroxyl-
ation in nogalamycin biosynthesis (Fig-
ure 1). The authors reconstitute this reac-
tion in vitro using the substrates, NAD(P)
H and the two enzymes SnoaW/SnoaL2.
No hydroxylation reaction was observed
with only one enzyme. An interesting
aspect is the detection of H2O2 in the
nonproductive SnoaW reaction, which
unequivocally demonstrates the presence
of a hydroperoxy intermediate during the
C-1hydroxylation reaction. In theabsence
of SnoaL2, the hydroperoxy intermediate
is readily oxidized back to its original
substrate. The striking similarity between
the formation of FMN hydroperoxide in
flavin-dependent monooxygenases (Val-
ton et al., 2006) and the formation of
anthracycline peroxy intermediate in
nogalamycin C-1 hydroxylation suggests
a route for the activation of molecular
oxygen by the substrate in its reduced di-
hydroquinone form, with the help of
SnoaW. Moreover, the authors also show
that the SnoaW reaction doesn’t proceed
without molecular oxygen. Together with
the detection of H2O2 in the SnoaW one-
enzyme reaction system, these results550 Chemistry & Biology 19, May 25, 2012 ªimply that the formationof thehydroperoxy
intermediate happens in the active site of
SnoaW and that this intermediate is the
substrate for SnoaL2. In the presence of
SnoaL2, the highly active intermediate is
protonated to form the final 1-hydroxyl-
ated product 30,40-memethoxy-nogalose-
1-hydroxy-nogalamycinone. From the
above observations, the authors deduce
that the mechanism for molecular oxygen
activation in the SnoaW/SnoaL2 system
is different from that in other characterized
two-component FMNmonooxygenases in
which the flavin is first reduced by the
reductases, transferred to the monooxy-
genase component, and then reacts with
O2 to form the C4a-(hydro)peroxyflavin
intermediate (Ballou et al., 2005). There-
fore, Siitonen et al. (2012) classify
SnoaW/SnoaL2 as a novel two-compo-
nent monooxygenase system.
In the in vitro assay, Siitonen et al.
(2012) also show that the SnoaW/SnoaL2
system prefers the mono-glycosylated
anthracycline over the nogalamycinone
aglycone as substrate. This substrate
preference suggests that the C-1 hydrox-
ylation of nogalamycin occurs at a rather
late stage. Crystallization analysis of the
enzymes-substrate complexes in the
future might help to reveal the catalytic2012 Elsevier Ltd All rights reservedmechanism behind this new family of
monooxygenases.
The inspiring characterization reported
by Siitonen et al. (2012) describes a new
type of two-component monooxygenase
with a different pattern for molecular
oxygen activation from other well studied
two-component FMN monooxygenases.
This is significant progress in revealing
the mechanism of action of cofactor-
independent monooxygenases as well
as in understanding the biosynthesis of
polyketide compounds. These findings
will greatly promote the discovery and
generation of novel clinically important
anthracyclines.
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